Fate Therapeutics, Inc.FATENASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank29
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-112.04M
Near historical average
Percentile
P29
Within normal range
Streak
3 yr
Consecutive growthContracting
Average
$-111.60M
Historical baseline
PeriodValueYoY Change
2025$-112.04M+9.4%
2024$-123.60M+10.7%
2023$-138.42M+51.2%
2022$-283.77M-32.9%
2021$-213.57M-383.6%
2020$-44.16M+51.2%
2019$-90.57M-121.2%
2018$-40.95M-6.0%
2017$-38.63M-27.6%
2016$-30.28M-